DIA Biosimilars 2013

Omnicare

Theorem names VP, EMEA

Wednesday, November 16, 2011 02:19 PM

Theorem Clinical Research, previously Omnicare Clinical Research, has named Christian Tucat vice president & general manager, Europe Middle East & Africa. In this role, Tucat will have direct accountability for sales and the P&L of Theorem’s business in these regions.

More... »

Cenduit: Now with Patient Reminders

Hoffman joins Theorem Clinical Research

Tuesday, November 8, 2011 03:35 PM

Theorem Clinical Research, previously Omnicare Clinical Research, has named Marc Hoffman, MD, senior vice president and general manager for their newly formed pharmaceutical development business unit. In his new role, Hoffman will have strategic oversight for Theorem’s core CRO operation, including project management, clinical monitoring, SMART (site management and patient recruitmenT), and pharmaceutics. He will also oversee the company’s medical operations. 

More... »

CRF Health – eCOA Forum

CRO top executives in a game of ‘musical chairs’

Monday, November 7, 2011 08:02 AM

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

More... »

Potthoff named president, CEO of Theorem Clinical Research

Wednesday, November 2, 2011 01:13 PM

John Potthoff has stepped down as chief operating officer of CRO INC Research to become president and CEO of Theorem Clinical Research, succeeding James Pusey, who now becomes Theorem’s executive chairman to the board of directors.

More... »

Theorem names VP, global business development

Thursday, October 27, 2011 12:22 PM

Theorem Clinical Research, previously Omnicare Clinical Research, has named Adam Serody vice president, global business development. In his new role, Serody will lead Theorem’s global sales, proposals and marketing organizations.

More... »

Carlyle Partners, Hellman & Friedman to acquire PPD for $3.9 billion, take the CRO private

Monday, October 10, 2011 08:02 AM

It’s official: Large equity investors Carlyle Partners and Hellman & Friedman Capital Partners are buying publicly traded PPD, taking the CRO private.

More... »

PPD names CEO, puts acquisition rumors in question

Monday, September 26, 2011 08:02 AM

PPD has named a new CEO, a move that strikes some in the industry as a little strange in the face of rumors that the publicly traded CRO is close to selling itself to a private equity firm.

More... »

PharMerica adopts poison pill to prevent takeover

Friday, August 26, 2011 01:25 PM

U.S. pharmacy services provider PharMerica adopted a poison pill to prevent hostile takeovers, two days after Omnicare went public with its bid to acquire the company for $441 million, according to Reuters.

More... »

Omnicare offers $457 million to buy PharMercia

Wednesday, August 24, 2011 01:12 PM

Omnicare went public with a $457 million offer for pharmacy management services company PharMerica, sending shares of both companies surging.

More... »

Omnicare names Thomas VP, GM of RxCrossroads

Tuesday, August 16, 2011 10:41 AM

Omnicare has named Dan Thomas senior vice president and general manager, RxCrossroads. In his new role, Thomas will have full operational responsibility for RxCrossroads, a leading provider of specialized solutions specifically tailored to the biotechnology and pharmaceutical industries.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs